Core Insights - BioNTech reported strong execution and pipeline momentum in 2025, with significant advancements in its oncology pipeline and a commitment to becoming a multi-product company by 2030 [3][5]. Financial Performance - For the full year 2025, BioNTech generated revenues of €2,869.9 million, an increase from €2,751.1 million in 2024, while the fourth quarter revenues were €907.4 million, down from €1,190.0 million in the same period last year [4][12]. - The company reported a net loss of €1,136.1 million for 2025, compared to a net loss of €665.3 million in 2024, with a diluted loss per share of €4.70, compared to a loss of €2.77 in the previous year [12][14]. - Adjusted net loss for the fourth quarter was €79.5 million, down from a profit of €432.4 million in the same quarter of 2024 [13][15]. Research and Development - R&D expenses for 2025 were €2,104.9 million, a decrease from €2,254.2 million in 2024, attributed to cost savings and active portfolio management [7][8]. - The company plans to focus on late-stage development and commercial readiness in oncology, with adjusted R&D expenses expected to be between €2.2 billion and €2.5 billion in 2026 [19]. Pipeline and Clinical Trials - BioNTech is on track for a catalyst-rich year in 2026, with six late-stage data readouts expected across various therapeutic areas, including immunomodulators and mRNA cancer immunotherapies [5][27]. - The company is advancing its bispecific immunomodulator pumitamig with eight global Phase 3 clinical trials planned in collaboration with Bristol Myers Squibb [5][27]. Corporate Developments - BioNTech co-founders are establishing an independent company focused on next-generation mRNA innovations, with a management transition expected by the end of 2026 [29]. - The company maintains a strong financial position with cash, cash equivalents, and security investments totaling €17.2 billion as of December 31, 2025 [16][17]. 2026 Financial Guidance - BioNTech anticipates total revenues for 2026 to be between €2.0 billion and €2.3 billion, with lower COVID-19 vaccine revenues expected compared to 2025 [18]. - Adjusted SG&A expenses for 2026 are projected to be between €700 million and €800 million [19].

Core Insights - BioNTech reported significant progress in its oncology strategy, particularly in advancing its pan-tumor programs and mRNA cancer immunotherapies, with a focus on pumitamig in collaboration with Bristol Myers Squibb [2][4][12] Financial Performance - Revenues for Q3 2025 reached €1,518.9 million, up from €1,244.8 million in Q3 2024, driven primarily by collaboration revenues with Bristol Myers Squibb [4][9] - Year-to-date revenues for 2025 were €1,962.5 million, compared to €1,561.1 million for the same period in 2024 [4] - The net loss for Q3 2025 was €28.7 million, a decline from a net profit of €198.1 million in Q3 2024 [9][10] - Basic and diluted loss per share for Q3 2025 was €0.12, compared to earnings per share of €0.82 in Q3 2024 [10] Research and Development - R&D expenses for Q3 2025 were €564.8 million, slightly higher than €550.3 million in Q3 2024, while year-to-date R&D expenses decreased to €1,599.5 million from €1,642.4 million [5][6] - The company is focusing on late-stage trials for immuno-oncology and antibody-drug conjugate programs, with cost savings from active portfolio management [5] Strategic Developments - BioNTech launched a variant-adapted COVID-19 vaccine for the 2025/2026 season and plans to initiate additional pivotal trials for pumitamig in various cancer types [6][18] - The company has strengthened its financial position with cash and equivalents totaling €16.7 billion, bolstered by a $1.5 billion payment from the Bristol Myers Squibb partnership [6][12] Guidance and Outlook - BioNTech increased its revenue guidance for the full 2025 financial year to a range of €2.6-2.8 billion, while lowering expense guidance for R&D, SG&A, and capital expenditures [12][13] - The company aims to maintain a focus on R&D investments and operational efficiency to support sustainable growth [14]

Financial Performance - Second quarter 2025 revenues reached €261 million, compared to €129 million in the second quarter of 2024[61] - First half 2025 revenues totaled €444 million, an increase from €316 million in the first half of 2024[61] - The company reported a net loss of €387 million for the second quarter of 2025, compared to a net loss of €808 million for the same period in 2024[61] - Research and Development expenses for the second quarter of 2025 were €509 million, compared to €585 million for the second quarter of 2024[61] - Cash and cash equivalents plus security investments reached approximately €160 billion as of June 30, 2025[12,61] Strategic Collaboration - BioNTech and Bristol Myers Squibb (BMS) entered into a strategic collaboration for BNT3271, with an upfront cash payment of $15 billion expected in Q3 2025[12,62] - The collaboration with BMS includes non-contingent anniversary cash payments of $20 billion from 2026 to 2028[62] - Potential development, regulatory, and commercial milestone cash payments from BMS could reach up to $76 billion[62] Pipeline Development - A Phase 2 study of BNT3271 combined with chemotherapy in 1L ES-SCLC showed an objective response rate (ORR) of 854% and a median overall survival (OS) of 168 months[29] - In a Phase 1b/2a study, BNT3271 monotherapy in 1L NSCLC (EGFR & ALK WT) showed an ORR of 47% and a median PFS of 136 months[34] - A Phase 1/2 study of BNT3271 combined with chemotherapy in 1L TNBC showed an ORR of 738% and a median PFS of 135 months[35]

This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including, but not limited to, statements concerning: BioNTech's expected revenues and net profit/(loss) related to sales of BioNTech's COVID-19 vaccine, referred to as COMIRNATY where approved for use under full or conditional marketing authorization, in territories controlled by BioNTech's collaboration partners, particularly for those figures that are derived from ...